前列腺癌（PC）被认为是一种异质性疾病。大约 20% 至 30% 的 PC 患者会出现癌症复发，其特征是血清前列腺特异性抗原 (PSA) 的抗原增加。 PC 的临床复发通常发生在五年后。转移性去势抵抗性前列腺癌（mCRPC）具有复杂的基因组背景。针对 DNA 修复信号通路基因组变化的疗法已逐渐获得临床批准。针对信号通路、骨生态位、免疫检查点和表观遗传标记等创新疗法已在更好地治疗骨转移 PC 病例方面取得了有希望的结果。这篇综述文章总结了最近对局部和转移性前列腺癌所涉及的分子机制和信号通路的思考，强调了新理解的临床暗示。版权所有© Bentham Science Publishers；如有任何疑问，请发送电子邮件至 epub@benthamscience.net。

Prostate cancer (PC) is identified as a heterogeneous disease. About 20 to 30% of PC patients experience cancer recurrence, characterized by an increase in the antigen termed serum prostate-specific antigen (PSA). Clinical recurrence of PC commonly occurs after five years. Metastatic castration-resistant prostate cancer (mCRPC) has an intricate genomic background. Therapies that target genomic changes in DNA repair signaling pathways have been progressively approved in the clinic. Innovative therapies like targeting signaling pathways, bone niche, immune checkpoint, and epigenetic marks have been gaining promising results for better management of PC cases with bone metastasis. This review article summarizes the recent consideration of the molecular mechanisms and signaling pathways involved in local and metastatic prostate cancer, highlighting the clinical insinuations of the novel understanding.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.